Richard Zuniga

790 total citations
16 papers, 498 citations indexed

About

Richard Zuniga is a scholar working on Cancer Research, Pulmonary and Respiratory Medicine and Genetics. According to data from OpenAlex, Richard Zuniga has authored 16 papers receiving a total of 498 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Cancer Research, 9 papers in Pulmonary and Respiratory Medicine and 6 papers in Genetics. Recurrent topics in Richard Zuniga's work include Glioma Diagnosis and Treatment (6 papers), Cancer Genomics and Diagnostics (6 papers) and Cancer, Hypoxia, and Metabolism (4 papers). Richard Zuniga is often cited by papers focused on Glioma Diagnosis and Treatment (6 papers), Cancer Genomics and Diagnostics (6 papers) and Cancer, Hypoxia, and Metabolism (4 papers). Richard Zuniga collaborates with scholars based in United States, Switzerland and France. Richard Zuniga's co-authors include Roy Torcuator, Rajan Jain, Thomas J. Doyle, John E. Anderson, T. Mikkelsen, Shehanaz Ellika, L. Schultz, Tom Mikkelsen, Jack Rock and Mark L. Rosenblum and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

Richard Zuniga

13 papers receiving 487 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Richard Zuniga United States	6	360	211	141	121	89	16	498
Roy Torcuator United States	8	451 1.3×	233 1.1×	132 0.9×	114 0.9×	84 0.9×	8	585
Pietro Ciccarino Italy	12	453 1.3×	150 0.7×	190 1.3×	168 1.4×	74 0.8×	21	583
Scott Peak United States	7	438 1.2×	281 1.3×	135 1.0×	131 1.1×	209 2.3×	9	640
Emese Filka United States	6	533 1.5×	202 1.0×	197 1.4×	240 2.0×	128 1.4×	9	672
Ivan Lolli Italy	13	388 1.1×	197 0.9×	202 1.4×	158 1.3×	190 2.1×	40	672
Debra C. LaFrankie United States	10	537 1.5×	201 1.0×	180 1.3×	200 1.7×	120 1.3×	19	701
T. Mikkelsen United States	11	515 1.4×	220 1.0×	205 1.5×	270 2.2×	134 1.5×	21	731
Thomas Urup Denmark	14	366 1.0×	120 0.6×	171 1.2×	192 1.6×	86 1.0×	30	585
Macarena I. de la Fuente United States	13	300 0.8×	79 0.4×	106 0.8×	153 1.3×	122 1.4×	36	510
Kirsten Grunnet Denmark	14	494 1.4×	179 0.8×	166 1.2×	151 1.2×	76 0.9×	25	588

Countries citing papers authored by Richard Zuniga

Since Specialization

Citations

This map shows the geographic impact of Richard Zuniga's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richard Zuniga with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richard Zuniga more than expected).

Fields of papers citing papers by Richard Zuniga

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Richard Zuniga. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richard Zuniga. The network helps show where Richard Zuniga may publish in the future.

Co-authorship network of co-authors of Richard Zuniga

This figure shows the co-authorship network connecting the top 25 collaborators of Richard Zuniga. A scholar is included among the top collaborators of Richard Zuniga based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Richard Zuniga. Richard Zuniga is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

Bourla, Ariel B., Katja Schulze, Sophia L. Maund, et al.. (2025). Real-world enrollment for a prospective clinico-genomic database using a pragmatic technology-enabled platform. Contemporary Clinical Trials Communications. 44. 101446–101446. 1 indexed citations

Madison, Russell W., Zoe J. Assaf, Alexander D. Fine, et al.. (2025). Real-World Validity of Tissue-Agnostic Circulating Tumor DNA Response Monitoring in Lung Cancers Treated With Chemotherapy, Immunotherapy, or Targeted Agents. JTO Clinical and Research Reports. 6(9). 100829–100829. 1 indexed citations

Ma, Esprit, Elaine Yu, Davey B. Daniel, et al.. (2025). A rising tide lifts all boats in the personalized cancer care continuum for mNSCLC: bridging inequities in NGS fosters equity in targeted treatment. The Oncologist. 30(5).

Arbour, Kathryn C., Ben George, Jason T. Henry, et al.. (2025). BMS-986504 in patients (pts) with advanced solid tumors with homozygous MTAP deletion ( MTAP -del): Clinical update and first report of pharmacokinetics (PK) and pharmacodynamic (PD) analyses from CA240-0007.. Journal of Clinical Oncology. 43(16_suppl). 3011–3011. 1 indexed citations

Vidal, Gregory A., Neha Jain, Aaron Fisher, et al.. (2024). Racial and Ethnic Inequities at the Practice and Physician Levels in Timely Next-Generation Sequencing for Patients With Advanced Non–Small-Cell Lung Cancer Treated in the US Community Setting. JCO Oncology Practice. 20(3). 370–377. 3 indexed citations

Madison, Russell W., Yanmei Huang, Alexander D. Fine, et al.. (2024). Abstract 971: Validation of a tumor-naïve circulating tumor DNA (ctDNA) response monitoring panel in advanced non-small cell lung cancer (aNSCLC). Cancer Research. 84(6_Supplement). 971–971. 5 indexed citations

Blau, Sibel, Margaret Block, Michael Danso, et al.. (2024). ACE-BREAST-03: A phase 2 trial evaluating ARX788, an anti-HER2 antibody drug conjugate (ADC), for the treatment of HER2+ metastatic breast cancer (mBC) in patients who have been previously treated with trastuzumab deruxtecan (T-DXd).. Journal of Clinical Oncology. 42(16_suppl). TPS1123–TPS1123. 2 indexed citations

Zuniga, Richard, et al.. (2023). 904 A case report of metastatic castration resistant prostate cancer patient with AR F877L mutation treated with KPG-121 in combination with enzalutamide. SHILAP Revista de lepidopterología. A1006–A1006. 1 indexed citations

Spigel, David R., Maen Hussein, Richard Zuniga, et al.. (2023). MyTACTIC: Afficacy and safety of atezolizumab (atezo) + chemotherapy (chemo) in patients (pts) with advanced unresectable/metastatic solid tumors with high tumor mutational burden (TMB-H) or high microsatellite instability (MSI-H)/deficient mismatch repair (dMMR).. Journal of Clinical Oncology. 41(16_suppl). 2612–2612. 1 indexed citations

10.

Holstein, Sarah A., Hira Mian, Cyrille Touzeau, et al.. (2023). PB2129: THE MODAKAFUSP ALFA IINNOVATE CLINICAL DEVELOPMENT PROGRAM: RATIONALE AND DESIGN OF 3 PHASE 1/2 TRIALS OF AN INNATE IMMUNITY ENHANCER FOR MULTIPLE MYELOMA (MM). HemaSphere. 7(S3). e9860835–e9860835.

11.

Brenner, Andrew, Richard Zuniga, Jessica D. Sun, et al.. (2018). Hypoxia-activated evofosfamide for treatment of recurrent bevacizumab-refractory glioblastoma: a phase I surgical study. Neuro-Oncology. 20(9). 1231–1239. 27 indexed citations

12.

Zuniga, Richard, Roy Torcuator, Rajan Jain, et al.. (2010). Rebound tumour progression after the cessation of bevacizumab therapy in patients with recurrent high-grade glioma. Journal of Neuro-Oncology. 99(2). 237–242. 64 indexed citations

13.

Torcuator, Roy, Richard Zuniga, Jack Rock, et al.. (2009). Initial experience with bevacizumab treatment for biopsy confirmed cerebral radiation necrosis. Journal of Neuro-Oncology. 94(1). 63–68. 148 indexed citations

14.

Torcuator, Roy, Richard Zuniga, Randa Loutfi, & Tom Mikkelsen. (2009). Bevacizumab and irinotecan treatment for progressive diffuse brainstem glioma: case report. Journal of Neuro-Oncology. 93(3). 409–412. 11 indexed citations

15.

Zuniga, Richard, Roy Torcuator, Rajan Jain, et al.. (2008). Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan. Journal of Neuro-Oncology. 91(3). 329–336. 224 indexed citations

16.

Zuniga, Richard, Roy Torcuator, Thomas J. Doyle, et al.. (2008). Retrospective analysis of patterns of recurrence seen on MRI in patients with recurrent glioblastoma multiforme treated with bevacizumab plus irinotecan. Journal of Clinical Oncology. 26(15_suppl). 13013–13013. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact